AstraZeneca links with Singapore for cancer research
This article was originally published in Scrip
Executive Summary
AstraZenecahas signed a memorandum of understanding to collaborate with two national facilities in Singapore for the preclinical and early clinical development of new drugs for hepatocellular carcinoma (HCC). This is part of a wider initiative determining which researchers from the Asian island state will also receive training in the UK.